Additionally, sunitinib malate, a multi-receptor tyrosine kinase inhibitor, has shown potential in inhibiting hemangioma cell growth and migration by suppressing focal adhesion kinase signaling and reducing the expression of adhesion proteins and tumor growth factor-β1 [67]. Here, NTRK1 is linked to hemangioma.